Cell News and Research

RSS

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.

1 Nov 2012

Exosomes alone could protect infants' lungs from dangerous inflammation

Researchers at Boston Children's Hospital have found that microscopic particles containing proteins and nucleic acids called exosomes could potentially protect the fragile lungs of premature babies from serious lung diseases and chronic lung injury caused by inflammation.

1 Nov 2012

Brain's infralimbic cortex can switch between new and old habits

Habits are behaviors wired so deeply in our brains that we perform them automatically. This allows you to follow the same route to work every day without thinking about it, liberating your brain to ponder other things, such as what to make for dinner.

1 Nov 2012

Scientists discover first selective inhibitors of DAGL enzymes

Scientists at The Scripps Research Institute (TSRI) have discovered the first selective inhibitors of an important set of enzymes. The new inhibitors, and chemical probes based on them, now can be used to study the functions of enzymes known as diacylglycerol lipases (DAGL), their products, and the pathways they regulate.

1 Nov 2012

Varian highlights numerous lung cancer treatment systems at ASTRO meeting

Varian Medical Systems highlighted the company's technologies for the non-invasive treatment of lung cancer at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston this week.

1 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Green tea may reduce risk of digestive system cancers among women

Women who drink green tea may lower their risk of developing some digestive system cancers, especially cancers of the stomach/esophagus and colorectum, according to a study led by researchers from Vanderbilt-Ingram Cancer Center.

1 Nov 2012

Scientists solve mystery behind what triggers the herpes virus to become active again

The mere mention of the word "herpes" usually conjures negative images and stereotypes, but most people have been infected with some form of the virus. For most, a sore appears, heals and is forgotten, although the virus remains latent just waiting for the right circumstances to come back. Now, the mystery behind what triggers the virus to become active again is closer to being solved thanks to new research published in the Journal of Leukocyte Biology's November 2012 issue.

1 Nov 2012

Biomarker discovery offers hope for lung cancer blood test

Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.

31 Oct 2012

Pins made of single atoms to fight cancer

Answers are often elusive in the fight against cancer, and Rice University chemist Zachary Ball is hoping to pin one down -- with pins made of single atoms. The work, which aims to create a drug that's effective against an "undruggable" protein, is one of the first 50 proposals funded under the National Cancer Institute's (NCI) Provocative Questions Project.

31 Oct 2012

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company, today announced that the European Commission has granted conditional marketing authorisation for ADCETRIS (brentuximab vedotin) for two indications.

31 Oct 2012

Viewpoints: Wilensky on 'ending Medicare as we've known it'; Abortion politics, the election and 'absolutists'

Democrats have charged Republicans with "ending Medicare as we've known it" and have been generally successful in making that claim stick in the mind of the public. The interesting fact is that Democrats have also "ended Medicare as we've known it" -- that is, as an open-ended entitlement -- but thus far, they seem to have escaped getting hit with the same label. If the [Independent Payment Advisory Board] ever actually goes into effect, it will be interesting to see whether they will continue to be successful at dodging their own charge.

31 Oct 2012

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

31 Oct 2012

ESDM intervention can change brain function in toddlers with autism spectrum disorders

An autism intervention program that emphasizes social interactions and is designed for children as young as 12 months has been found to improve cognitive skills and brain responses to faces, considered a building block for social skills. The researchers say that the study, which was completed at the University of Washington, is the first to demonstrate that an intensive behavioral intervention can change brain function in toddlers with autism spectrum disorders.

31 Oct 2012

Viscus Biologics to develop and commercialize NFB’s new tissue repair material

Viscus Biologics LLC, Cleveland, Ohio, has secured an 18-month option to conduct further research into the development and commercialisation of a new tissue repair material developed by the Network of Excellence for Functional Biomaterials (NFB) at National University of Ireland, Galway.

31 Oct 2012

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a "lost generation" of sufferers-children, young adults and adolescents.

31 Oct 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

Unique bond between SAP102 and GluN2B enables learning and memory

Two proteins have a unique bond that enables brain receptors essential to learning and memory to not only get and stay where they're needed, but to be hauled off when they aren't, researchers say.

31 Oct 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Complix to accelerate development of CPABs against intracellular disease targets

Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).

30 Oct 2012